TY - JOUR
T1 - Cerebral effects of glucagon-like peptide-1 receptor blockade before and after Roux-en-Y gastric bypass surgery in obese women: A proof-of-concept resting-state functional MRI study
T2 - A proof-of-concept resting-state functional MRI study
AU - van Duinkerken, Eelco
AU - Bernardes, Gabriel
AU - van Bloemendaal, Liselotte
AU - Veltman, Dick J.
AU - Barkhof, Frederik
AU - Mograbi, Daniel C.
AU - Gerdes, Victor E. A.
AU - Deacon, Carolyn F.
AU - Holst, Jens J.
AU - Drent, Madeleine L.
AU - Diamant, Michaela
AU - ten Kulve, Jennifer
AU - Ijzerman, Richard G.
N1 - Funding Information:
F.B. is supported by the NIHR Biomedical Research Center at UCLH.
Funding Information:
C.F.D. has received consultancy/speaker fees from Bristol‐Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme, Novartis and Novo Nordisk. J.J.H. has received fees for consulting, lecturing and/or being part of an advisory board from AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly and Company, GI Dynamics, Merck Sharp & Dohme, Novo Nordisk, Novartis, Sanofi, Takeda and Zealand Pharma. M.D. was a consultant for Abbott, AstraZeneca, Bristol‐Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, GI Dynamics, Merck Sharp & Dohme, Novo Nordisk, Poxel SA and Sanofi and was a speaker for BristolMyers Squibb/AstraZeneca, Eli Lilly and Company, Novo Nordisk and Sanofi. Through M.D., the VU University Medical Center received research grants from Abbott, Bristol‐Myers Squibb/AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Medtronic, Merck Sharp & Dohme, Novo Nordisk and Sanofi. R.G.I. is the principal investigator of studies sponsored by research grants from Novo Nordisk and Eli Lilly and Company. M.D. and R.G.I. report receiving no personal payments in connection to the above‐mentioned activities, but all payments were directly transferred to the Diabetes Center (VU University Medical Center) non‐profit research foundation. No other potential conflicts of interest relevant to this article were reported.
Funding Information:
F.B. is supported by the NIHR Biomedical Research Center at UCLH.
Funding Information:
F.B. is supported by the National Institute of Health Research Biomedical Research Center at University College London Hospitals. Funding information
Publisher Copyright:
© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
PY - 2021/2
Y1 - 2021/2
N2 - Aim: To assess the effects of Roux-en-Y gastric bypass surgery (RYGB)-related changes in glucagon-like peptide-1 (GLP-1) on cerebral resting-state functioning in obese women. Materials and Methods: In nine obese females aged 40-54 years in the fasted state, we studied the effects of RYGB and GLP-1 on five a priori selected networks implicated in food- and reward-related processes as well as environment monitoring (default mode, right frontoparietal, basal ganglia, insula/anterior cingulate and anterior cingulate/orbitofrontal networks). Results: Before surgery, GLP-1 receptor blockade (using exendin9-39) was associated with increased right caudate nucleus (basal ganglia network) and decreased right middle frontal (right frontoparietal network) connectivity compared with placebo. RYGB resulted in decreased right orbitofrontal (insula/anterior cingulate network) connectivity. In the default mode network, after surgery, GLP-1 receptor blockade had a larger effect on connectivity in this region than GLP-1 receptor blockade before RYGB (all PFWE <.05). Results remained similar after correction for changes in body weight. Default mode and right frontoparietal network connectivity changes were related to changes in body mass index and food scores after RYGB. Conclusions: These findings suggest GLP-1 involvement in resting-state networks related to food and reward processes and monitoring of the internal and external environment, pointing to a potential role for GLP-1–induced changes in resting-state connectivity in RYGB-mediated weight loss and appetite control.
AB - Aim: To assess the effects of Roux-en-Y gastric bypass surgery (RYGB)-related changes in glucagon-like peptide-1 (GLP-1) on cerebral resting-state functioning in obese women. Materials and Methods: In nine obese females aged 40-54 years in the fasted state, we studied the effects of RYGB and GLP-1 on five a priori selected networks implicated in food- and reward-related processes as well as environment monitoring (default mode, right frontoparietal, basal ganglia, insula/anterior cingulate and anterior cingulate/orbitofrontal networks). Results: Before surgery, GLP-1 receptor blockade (using exendin9-39) was associated with increased right caudate nucleus (basal ganglia network) and decreased right middle frontal (right frontoparietal network) connectivity compared with placebo. RYGB resulted in decreased right orbitofrontal (insula/anterior cingulate network) connectivity. In the default mode network, after surgery, GLP-1 receptor blockade had a larger effect on connectivity in this region than GLP-1 receptor blockade before RYGB (all PFWE <.05). Results remained similar after correction for changes in body weight. Default mode and right frontoparietal network connectivity changes were related to changes in body mass index and food scores after RYGB. Conclusions: These findings suggest GLP-1 involvement in resting-state networks related to food and reward processes and monitoring of the internal and external environment, pointing to a potential role for GLP-1–induced changes in resting-state connectivity in RYGB-mediated weight loss and appetite control.
KW - appetite control, bariatric surgery, GLP-1, weight control
UR - https://www.scopus.com/pages/publications/85096698914
U2 - 10.1111/dom.14233
DO - 10.1111/dom.14233
M3 - Article
C2 - 33084088
SN - 1462-8902
VL - 23
SP - 415
EP - 424
JO - Diabetes, obesity & metabolism
JF - Diabetes, obesity & metabolism
IS - 2
ER -
SDG 3 Good Health and Well-being